Literature DB >> 11687449

Functional antibody activity elicited by fractional doses of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate).

S Romero-Steiner1, J Fernandez, C Biltoft, M E Wohl, J Sanchez, J Feris, S Balter, O S Levine, G M Carlone.   

Abstract

We evaluated the functional activities of antibodies, serum bactericidal activity (SBA), and immunoglobulin G (IgG) antibody avidity indices, using sodium thiocyanate (NaSCN) elution, elicited after vaccination with fractional doses of the Haemophilus influenzae type b conjugate (polyribosylribitol phosphate [PRP] conjugated to tetanus toxoid [PRP-T]) vaccine. A cohort of 600 infants from the Dominican Republic were randomized to receive one of three regimens of the PRP-T vaccine at ages 2, 4, and 6 months: full doses (10 microg of PRP antigen), one-half doses (5.0 microg), and one-third doses (3.3 microg) (J. Fernandez et al., Am. J. Trop. Med. Hyg. 62:485-490, 2000). Sixty serum samples, collected at age 7 months, with > or =2.0 microg of anti-PRP IgG per ml were randomly selected for avidity determinations. Geometric mean IgG concentrations were 13, 14, and 17 microg/ml for infants who received the full-dose (n = 19), one-half-dose (n = 19), and one-third-dose (n = 22) regimens, respectively. SBA geometric mean titers (1/dilution) were 85.0, 82.0, and 76.1 in sera from infants receiving the full-, one-half-, and one-third-dose regimens, respectively. Avidity indices (mean +/- standard error weighted average of NaSCN molar concentration x serum dilution factor) were 71.9 +/- 9.4, 123.6 +/- 26.8, and 150.9 +/- 24.9 for the full-, one-half-, and one-third-dose regimens, respectively. Upon comparison, the only significant difference (P = 0.024) found was a greater avidity index for sera from infants receiving the one-third-dose regimen than for sera from infants receiving the the full-dose regimen. We conclude that fractional doses elicit similar functional antibody activities in infants with > or = 2 microg of anti-PRP IgG per ml, corresponding to 89, 90, and 97% of infants receiving three doses of either the full concentration or one-half or one-third of the labeled concentration, respectively. This approach offers an alternative strategy for the prevention of H. influenzae type b disease in countries with limited resources.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11687449      PMCID: PMC96235          DOI: 10.1128/CDLI.8.6.1115-1119.2001

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  22 in total

1.  Haemophilus influenzae type B infection.

Authors:  O Levine; J Wenger; Y B Perkins; N Rosenstein; A Schuchat
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

2.  Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants.

Authors:  K Mulholland; S Hilton; R Adegbola; S Usen; A Oparaugo; C Omosigho; M Weber; A Palmer; G Schneider; K Jobe; G Lahai; S Jaffar; O Secka; K Lin; C Ethevenaux; B Greenwood
Journal:  Lancet       Date:  1997-04-26       Impact factor: 79.321

3.  Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens.

Authors:  R Lagos; M T Valenzuela; O S Levine; G A Losonsky; A Erazo; S S Wasserman; M M Levine
Journal:  Lancet       Date:  1998-05-16       Impact factor: 79.321

4.  Progress toward elimination of Haemophilus influenzae type b disease among infants and children--United States, 1987-1995.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1996-10-25       Impact factor: 17.586

5.  Immunogenicity and safety of Haemophilus influenzae type b polysaccharide-Neisseria meningitidis conjugate vaccine in 7.5 micrograms liquid formulation: a comparison of three lots with the 15.0 micrograms lyophilized formulation. Study Group for 7.5 micrograms Liquid PedvaxHIB.

Authors:  P M Mendelman; L Feeley; S Bird; T Staub; H Matthews; M A Del Beccaro; G Overturf; A Lee; R Ellis; J Staub; S Szymanski; J Donnelly; J P Hennessey; P Kniskern
Journal:  Vaccine       Date:  1997 Apr-May       Impact factor: 3.641

Review 6.  Difficulties in establishing a serological correlate of protection after immunization with Haemophilus influenzae conjugate vaccines.

Authors:  H Käyhty
Journal:  Biologicals       Date:  1994-12       Impact factor: 1.856

7.  Determination of parallelism and nonparallelism in bioassay dilution curves.

Authors:  B D Plikaytis; P F Holder; L B Pais; S E Maslanka; L L Gheesling; G M Carlone
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

8.  Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization.

Authors:  D Goldblatt; A R Vaz; E Miller
Journal:  J Infect Dis       Date:  1998-04       Impact factor: 5.226

9.  Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections.

Authors:  R Lagos; I Horwitz; J Toro; O San Martin; P Abrego; C Bustamante; S S Wasserman; O S Levine; M M Levine
Journal:  Pediatr Infect Dis J       Date:  1996-03       Impact factor: 2.129

10.  The epidemiology of Haemophilus influenzae type b carriage among infants and young children in Santo Domingo, Dominican Republic.

Authors:  E Gómez; A Moore; J Sánchez; J Kool; P L Castellanos; J M Feris; M Kolczak; O S Levine
Journal:  Pediatr Infect Dis J       Date:  1998-09       Impact factor: 2.129

View more
  17 in total

1.  Measurement of serum bactericidal activity specific for Haemophilus influenzae type b by using a chromogenic and fluorescent metabolic indicator.

Authors:  Sandra Romero-Steiner; Willie Spear; Nekeidra Brown; Patricia Holder; Thomas Hennessy; Patricia Gomez De Leon; George M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

2.  Immune response to Haemophilus influenzae type b vaccination in patients with chronic renal failure.

Authors:  Nicole Hawdon; Eli B Nix; Raymond S W Tsang; Garry Ferroni; William G McCready; Marina Ulanova
Journal:  Clin Vaccine Immunol       Date:  2012-04-25

3.  Immunologic response to Haemophilus influenzae type b (Hib) conjugate vaccine and risk factors for carriage among Hib carriers and noncarriers in Southwestern Alaska.

Authors:  Henry C Baggett; Thomas W Hennessy; Lisa Bulkow; Sandra Romero-Steiner; Debra Hurlburt; Patricia Holder; Alan J Parkinson; Rosalyn J Singleton; Orin Levine; George M Carlone; Jay C Butler
Journal:  Clin Vaccine Immunol       Date:  2006-06

Review 4.  A capsule conjugate vaccine approach to prevent diarrheal disease caused by Campylobacter jejuni.

Authors:  Alexander C Maue; Frédéric Poly; Patricia Guerry
Journal:  Hum Vaccin Immunother       Date:  2014-03-14       Impact factor: 3.452

5.  Risk of invasive Haemophilus influenzae type b (Hib) disease in adults with secondary immunodeficiency in the post-Hib vaccine era.

Authors:  Eli B Nix; Nicole Hawdon; Sean Gravelle; Birubi Biman; Malcolm Brigden; Saleem Malik; William McCready; Garry Ferroni; Marina Ulanova
Journal:  Clin Vaccine Immunol       Date:  2012-03-07

6.  Avidity determinations for Haemophilus influenzae Type b anti-polyribosylribitol phosphate antibodies.

Authors:  Sandra Romero-Steiner; Patricia F Holder; Patricia Gomez de Leon; Willie Spear; Thomas W Hennessy; George M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  2005-09

7.  Phase I clinical evaluation of a synthetic oligosaccharide-protein conjugate vaccine against Haemophilus influenzae type b in human adult volunteers.

Authors:  Gilda Toraño; Maria E Toledo; Alberto Baly; Violeta Fernandez-Santana; Francisco Rodriguez; Yunia Alvarez; Teresita Serrano; Alexis Musachio; Ibis Hernandez; Eugenio Hardy; Arlene Rodríguez; Hector Hernandez; Aristides Aguilar; Raydel Sánchez; Manuel Diaz; Verena Muzio; Jorgelina Dfana; Maria C Rodríguez; Lazaro Heynngnezz; Vicente Verez-Bencomo
Journal:  Clin Vaccine Immunol       Date:  2006-09

8.  Comparison of antibody repertoires against Staphylococcus aureus in healthy individuals and in acutely infected patients.

Authors:  Agnieszka Dryla; Sonja Prustomersky; Dieter Gelbmann; Markus Hanner; Edith Bettinger; Béla Kocsis; Tamás Kustos; Tamás Henics; Andreas Meinke; Eszter Nagy
Journal:  Clin Diagn Lab Immunol       Date:  2005-03

9.  The immunogenicity and safety of a reduced PRP-content DTPw-HBV/Hib vaccine when administered according to the accelerated EPI schedule.

Authors:  Sukanta Chatterjee; Sylvan J Rego; Fulton D'Souza; B D Bhatia; Alix Collard; Sanjoy K Datta; Jeanne-Marie Jacquet
Journal:  BMC Infect Dis       Date:  2010-10-15       Impact factor: 3.090

10.  Immunoglobulin G avidities in infants in Mexico after primary immunization with three doses of polyribosylribitol phosphate-tetanus toxoid Haemophilus influenzae type b vaccine.

Authors:  Patricia Gómez-de-León; F Javier Díaz-García; Alberto Villaseñor-Sierra; Jorge Segura; Martha I Carranza; José Luis Arredondo-Garcia; José Ignacio Santos
Journal:  Clin Vaccine Immunol       Date:  2008-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.